CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 8,439	$ 13
Prepaid expenses and other current assets	1,823	1,577
Total current assets	10,262	1,590
Property and equipment, net	200	235
Operating lease right-of-use asset	1,171	1,288
Other assets	29	29
Total assets	11,662	3,142
Current liabilities:
Accounts payable	3,907	5,910
Accrued clinical trials expenses	1,675	3,571
Accrued compensation	546	1,068
Other accrued expenses	3,001	3,600
Total current liabilities	9,129	14,149
Convertible notes at fair value, including related party amount of $15,174 and $11,689, at June 30, 2025 and December 31, 2024, respectively	15,174	11,689
Operating lease liability	1,020	1,145
Warrant liability	2,122	1,187
Contingent consideration liability	69	3,541
Total liabilities	27,514	31,711
Commitments and contingencies
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at June 30, 2025 and December 31, 2024, and 11,537,870 and 555,511 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	9	4
Additional paid-in capital	413,283	403,024
Accumulated deficit	(429,144)	(431,597)
Total stockholders' deficit	(15,852)	(28,569)
Total liabilities and stockholders' deficit	$ 11,662	$ 3,142